AgingResearch.NewsJoin free

AAV-DOK7

Intervention

2 papers7 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Japan Society for the Promotion of Science and 3 more
  • Animals2

Outcomes

5

Lifespan

upin mice2

2 studies

  1. AAV-DOK7 extends lifespan in mice.

    “DOK7 gene therapy enhanced motor activity and life span in ALS model mice”

    Animalsin ALS model mice

    DOK7 gene therapy enhances motor activity and life span in ALS model mice

    EMBO molecular medicine1 Jul 2017

  2. AAV-DOK7 extends lifespan in mice.

    “DOK7 gene resulted in an enlargement of NMJs and substantial increases in muscle strength and life span.”

    Animalsin a mouse model of DOK7 myasthenia

    Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction

    Science (New York, N.Y.)19 Sep 2014

Motor activity

upin mice2

2 studies

  1. AAV-DOK7 improves motor activity in mice.

    “DOK7 gene therapy enhanced motor activity and life span in ALS model mice”

    Animalsin ALS model mice

    DOK7 gene therapy enhances motor activity and life span in ALS model mice

    EMBO molecular medicine1 Jul 2017

  2. AAV-DOK7 improves motor activity in mice.

    “DOK7 gene therapy likewise resulted in enlargement of NMJs as well as positive effects on motor activity”

    Animalsin model mice of autosomal dominant Emery-Dreifuss muscular dystrophy

    Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction

    Science (New York, N.Y.)19 Sep 2014

Muscle atrophy

downin mice1

1 study

  1. AAV-DOK7 decreases muscle atrophy in mice.

    “suppressed motor nerve terminal degeneration at NMJs together with muscle atrophy in the SOD1-G93A ALS mouse model”

    Animalsin SOD1-G93A ALS mouse model

    DOK7 gene therapy enhances motor activity and life span in ALS model mice

    EMBO molecular medicine1 Jul 2017

Motor nerve terminal degeneration

downin mice1

1 study

  1. AAV-DOK7 decreases motor nerve terminal degeneration in mice.

    “suppressed motor nerve terminal degeneration at NMJs together with muscle atrophy in the SOD1-G93A ALS mouse model”

    Animalsin SOD1-G93A ALS mouse model

    DOK7 gene therapy enhances motor activity and life span in ALS model mice

    EMBO molecular medicine1 Jul 2017

Muscle strength

upin mice1

1 study

  1. AAV-DOK7 improves muscle strength in mice.

    “therapeutic administration of an adeno-associated virus (AAV) vector encoding the human DOK7 gene resulted in an enlargement of NMJs and substantial increases in muscle strength”

    Animalsin a mouse model of DOK7 myasthenia

    Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction

    Science (New York, N.Y.)19 Sep 2014

Latest

Related